Litigation Details for Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited (D. Del. 2015)

« Back to Dashboard

Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited (D. Del. 2015)

Docket		Date Filed	2015-01-14
Court	District Court, D. Delaware	Date Terminated	2018-04-09
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,713,446; 6,958,319
Link to Docket	External link to docket

Details for Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-14				External link to document
2015-01-13	1		18. United States Patent No. 6,713,446 (“the ’446 patent”), entitled “Formulation of Boronic…Injection prior to the expiration of U.S. Patent Nos. 6,713,446 and 6,958,319. … INFRINGEMENT OF U.S. PATENT NO. 6,713,446 27. Millennium incorporates… 1. This is an action for patent infringement under the patent laws of the United States, Title… 19. United States Patent No. 6,958,319 (“the ’319 patent”), entitled “Formulation of Boronic	External link to document
2015-01-13	3		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,713,446 B2; 6,958,319 B2. (…2015 9 April 2018 1:15-cv-00040 830 Patent None District Court, D. Delaware	External link to document

Millennium Pharmaceuticals v. Mylan Laboratories: Velcade Patent Litigation Summary and Analysis

Last updated: September 25, 2026

Millennium Pharmaceuticals sued Mylan Laboratories in the U.S. District Court for the District of Delaware over Mylan’s abbreviated new drug application for generic bortezomib, the active ingredient in Velcade. The case, 1:15-cv-00040, was part of broader ANDA litigation involving Millennium’s patented bortezomib formulation.

The dispute focused primarily on whether Mylan’s proposed generic product would infringe Millennium patents covering lyophilized bortezomib formulations and whether those patents were valid. The most commercially significant patents were U.S. Patent Nos. 6,713,446 and 8,268,801. The Federal Circuit later upheld the validity of those patents in related litigation against Sandoz, strengthening Millennium’s negotiating position across the Velcade generic landscape. [1]

What was Millennium Pharmaceuticals v. Mylan Laboratories about?

Millennium filed the action after receiving notice of Mylan’s Paragraph IV certification concerning patents listed for Velcade in the FDA Orange Book. The lawsuit sought to prevent FDA approval or commercial launch of Mylan’s generic bortezomib product before expiration of the asserted patents.

Drug and product at issue

Item	Details
Brand drug	Velcade
Active ingredient	Bortezomib
Therapeutic class	Proteasome inhibitor
Primary indications	Multiple myeloma and mantle cell lymphoma
Brand sponsor	Millennium Pharmaceuticals, later part of Takeda
Generic pathway	ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00040
Filing date	January 16, 2015
Plaintiff	Millennium Pharmaceuticals, Inc.
Defendants	Mylan Laboratories Limited and affiliated Mylan entities

Velcade is supplied as a sterile lyophilized powder that is reconstituted before administration. Millennium’s formulation patents addressed the use of mannitol and related formulation characteristics that improved product stability and produced a suitable bortezomib-mannitol ester during lyophilization. [1]

What patents protected Velcade in the Mylan litigation?

The central patent family included patents covering bortezomib formulations rather than only the underlying chemical compound.

Patent	General subject matter	Relevance
U.S. Patent No. 6,713,446	Lyophilized bortezomib formulation containing mannitol	Core formulation patent
U.S. Patent No. 8,268,801	Further claims directed to bortezomib-mannitol formulations and product characteristics	Later formulation patent
Related Velcade patents	Additional formulation and product claims	Potentially relevant to other ANDA defendants

The '446 patent was particularly important because its claims covered a pharmaceutical composition containing bortezomib and mannitol in a lyophilized form. The '801 patent provided additional protection for formulation attributes and manufacturing-related aspects.

The Federal Circuit’s decision in Millennium Pharmaceuticals, Inc. v. Sandoz Inc. held that asserted claims of the '446 and '801 patents were not obvious. The court rejected the argument that a skilled artisan would have had a reasonable expectation of success in producing the claimed formulation from the prior art. [1]

That ruling materially affected the Mylan case because it removed a principal invalidity argument available to ANDA defendants challenging the same patent estate.

What was Mylan’s Paragraph IV challenge?

Mylan’s ANDA included a Paragraph IV certification asserting that the relevant Millennium patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed product. Under the Hatch-Waxman Act, the certification gave Millennium a statutory basis to file an infringement action.

The filing of the lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the timing and procedural status of the litigation. The stay prevented FDA approval during the statutory period unless the court issued a decision earlier resolving the relevant patent issues.

Mylan’s likely invalidity and noninfringement positions

The principal defenses in this class of Velcade litigation included:

1. The claimed formulation was obvious in view of known bortezomib chemistry and conventional lyophilization techniques.
2. The prior art disclosed mannitol as a common bulking agent and excipient.
3. The proposed Mylan product did not meet one or more claim limitations.
4. The patents were invalid for lack of written description or enablement.
5. The asserted claims were not enforceable based on prosecution or inequitable-conduct theories, if supported by the record.

The Federal Circuit’s later ruling in the Sandoz appeal reduced the force of the obviousness defense. The court found that the prior art did not provide a sufficient reason or reasonable expectation of success for producing the claimed stable bortezomib formulation. [1]

How did the Mylan case compare with the Sandoz Velcade litigation?

The Mylan and Sandoz proceedings arose from the same commercial product and overlapping patent estate, but the best-known merits decision came from the Sandoz case.

Issue	Mylan case	Sandoz case
Product	Generic bortezomib	Generic bortezomib
Court	District of Delaware	District of Delaware, followed by Federal Circuit appeal
Key patents	'446 and related Velcade formulation patents	'446 and '801
Core defense	Invalidity and noninfringement	Primarily obviousness
Public merits ruling	No comparable Federal Circuit merits opinion	Federal Circuit affirmed validity
Commercial effect	ANDA launch timing constrained by patent litigation	Validity ruling strengthened Millennium’s position

The Federal Circuit described the claimed formulation as involving a result that was not predictable from the prior art. The court emphasized that the prior art did not show that mannitol would produce the claimed bortezomib-mannitol formulation or that the resulting product would have the required stability and performance. [1]

For Millennium, that decision had collateral value in negotiations with other generic applicants, including Mylan. A patent holder with a favorable appellate validity ruling generally has more leverage in settlement negotiations, launch-date negotiations, and later litigation.

What was the litigation status and outcome?

The public docket for 1:15-cv-00040 reflects a Hatch-Waxman action that was resolved without a reported trial judgment comparable to the Federal Circuit’s decision in the Sandoz matter. The case did not produce a published appellate ruling establishing that Mylan’s product infringed the asserted claims or that the patents were invalid.

The absence of a merits opinion does not mean the litigation lacked commercial effect. ANDA cases are often resolved through confidential or partially confidential settlement agreements, stipulated dismissals, or negotiated launch arrangements. Public docket activity may establish that claims were dismissed while leaving the economic terms of a settlement undisclosed.

Settlement and generic launch implications

The docket record should be read separately from the regulatory status of Mylan’s ANDA:

• A dismissal does not itself establish that Mylan was permitted to launch immediately.
• A settlement may include a delayed launch date, a license, supply restrictions, or other commercial terms.
• Confidential settlement provisions may not appear in the public docket.
• The FDA may approve an ANDA after patent barriers expire, are removed, or are otherwise resolved under Hatch-Waxman procedures.

The case therefore should not be characterized as a judicial defeat for Millennium. The more accurate characterization is that the litigation ended without a publicly reported merits decision against Millennium, while related appellate litigation strengthened the validity position of the core formulation patents.

What was the Orange Book status of Velcade?

Velcade was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Orange Book-listed patents can trigger a statutory stay when an ANDA applicant files a Paragraph IV certification and the brand company brings a timely infringement action.

The relevant patent protections were different in scope:

• Compound patents protected bortezomib itself.
• Formulation patents protected the lyophilized dosage form and excipient combination.
• Method-of-use patents could protect particular treatment regimens or indications.
• Manufacturing-related claims could create additional barriers if they covered steps practiced by a generic manufacturer.

For an injectable product, formulation and manufacturing patents can be commercially important even after basic compound protection expires. The generic applicant must evaluate the composition as sold, the reconstitution process, the manufacturing process, and the labeling used for FDA approval.

When did Velcade lose exclusivity?

Velcade’s exclusivity ended in stages rather than on a single date.

Protection type	Commercial significance
FDA regulatory exclusivity	Limited period tied to the original approval and any qualifying supplements
Compound patent protection	Protected bortezomib as a chemical entity
Formulation patent protection	Protected the commercial lyophilized product
Pediatric exclusivity	Could extend relevant listed patent and regulatory periods
Litigation stay	Delayed FDA approval during the statutory Hatch-Waxman period

The '446 patent had an expiration date in the early 2020s, subject to any applicable patent-term adjustment or extension. The '801 patent had a later expiration date and was directed to additional formulation protection. Precise market-entry timing depended on the patents listed for the specific ANDA, the Paragraph IV certifications, any settlement terms, and the FDA’s regulatory determination.

Generic bortezomib competition ultimately became commercially feasible as the principal Velcade patent barriers expired or were otherwise resolved. The litigation did not create a permanent barrier to generic entry.

How strong was Millennium’s Velcade patent estate?

Millennium’s patent estate was stronger on formulation validity than a conventional formulation portfolio might initially appear.

Strengths

• The Federal Circuit affirmed the validity of key formulation claims in related litigation.
• The claimed formulation involved an unexpected chemical interaction between bortezomib and mannitol.
• The product was an injectable lyophilized dosage form with specific manufacturing and stability requirements.
• The patents covered product characteristics that could be difficult for a generic applicant to avoid while matching the reference product.

Limitations

• Formulation patents eventually expire.
• A successful validity ruling against one defendant does not automatically establish infringement by another defendant.
• Claim scope is limited to the precise formulation and process elements recited in each patent.
• A generic manufacturer may design around particular excipient ratios, reconstitution characteristics, or manufacturing steps.
• Confidential settlements prevent complete public analysis of launch dates and economic concessions.

The estate was commercially meaningful but time-limited. Its strongest value was the ability to delay or negotiate generic entry during the remaining patent term, not to exclude competition indefinitely.

What generic entry risks existed for Velcade?

Velcade faced several generic-entry scenarios:

1. A first-filer could obtain 180-day exclusivity if it satisfied the statutory requirements and maintained eligibility.
2. A later filer could enter after settlement or patent expiration.
3. A generic could launch after obtaining a judgment of noninfringement or invalidity.
4. A product could launch after a licensed date established in a settlement.
5. A manufacturer could enter with a product designed around nonessential formulation limitations.

The principal risk to Millennium was erosion of Velcade revenue from injectable bortezomib products. Because Velcade was a major oncology product, generic substitution had the potential to produce rapid price compression after multiple ANDAs became available.

What litigation affected Velcade revenue exposure?

Velcade generated multibillion-dollar annual sales for Millennium and later Takeda before generic erosion. Takeda reported Velcade as a major oncology product in its annual reporting, with sales exposed to patent expiry and generic competition. [2]

The commercial exposure was concentrated in:

• U.S. hospital and oncology-clinic use;
• Multiple myeloma treatment;
• Mantle cell lymphoma treatment;
• Repeated treatment cycles;
• Injectable product supply and reimbursement economics.

Generic entry risk was higher after multiple manufacturers secured approval because injectable oncology products can experience rapid price decline once institutional buyers have several suppliers.

Key Takeaways

• Millennium sued Mylan in the District of Delaware over an ANDA for generic bortezomib.
• The litigation concerned Velcade formulation patents, principally U.S. Patent Nos. 6,713,446 and 8,268,801.
• Mylan’s Paragraph IV certification created the basis for the Hatch-Waxman infringement action and a potential 30-month FDA approval stay.
• The Mylan case ended without a reported merits judgment comparable to the Federal Circuit’s Sandoz decision.
• The Federal Circuit later upheld the validity of key Millennium formulation claims in related litigation.
• The appellate ruling improved Millennium’s settlement leverage across the Velcade ANDA cases.
• Generic entry ultimately depended on patent expiration, settlement terms, FDA approval, and the scope of each applicant’s ANDA certifications.
• The patent estate delayed generic competition but did not eliminate long-term erosion of Velcade revenue.

FAQs About Millennium v. Mylan and Velcade Patent Litigation

Did Mylan win the Velcade patent case?

The public record does not show a reported merits victory for Mylan or a published judgment invalidating Millennium’s patents. The case was resolved without the type of appellate merits ruling issued in the related Sandoz litigation.

Which patents covered the Velcade formulation?

The principal formulation patents associated with the litigation were U.S. Patent Nos. 6,713,446 and 8,268,801. They covered lyophilized bortezomib formulations involving mannitol and related formulation characteristics.

Did the Federal Circuit decide the Mylan case?

No. The significant Federal Circuit decision involved Millennium Pharmaceuticals v. Sandoz, not the Mylan docket. That decision nevertheless affected the legal and commercial analysis of overlapping Velcade patent disputes.

Could Mylan launch generic bortezomib before all Velcade patents expired?

Potentially, but only through a license, a successful noninfringement or invalidity result, a permitted settlement launch date, or another resolution of the relevant patent and regulatory barriers.

Was Velcade protected by formulation patents after compound patent expiry?

Yes. Velcade’s formulation patents extended protection beyond the basic chemical-entity patent strategy. Those patents focused on the injectable lyophilized product and the bortezomib-mannitol formulation.

References

1. U.S. Court of Appeals for the Federal Circuit. (2017). Millennium Pharmaceuticals, Inc. v. Sandoz Inc., 862 F.3d 1356.

2. Takeda Pharmaceutical Company Limited. (2015). Annual report 2015. Takeda Pharmaceutical Company Limited.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. District Court for the District of Delaware. (2015). Millennium Pharmaceuticals, Inc. v. Mylan Laboratories Limited et al., No. 1:15-cv-00040. Docket record.

5. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,713,446, Boron-containing compounds and pharmaceutical compositions. USPTO.

6. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,268,801, Formulations of bortezomib. USPTO.